1. P757 Long-term effectiveness and safety of adalimumab based on Crohn's disease duration: Results from the PYRAMID registry. (16th January 2018) Authors: Loftus Jr, E V; Reinisch, W; Panaccione, R; Berg, S; Bereswill, M; Kalabic, J; Skup, M; Petersson, J; Robinson, A M; D'Haens, G Journal: Journal of Crohn's and colitis Issue: Volume 12:Number 1(2018:Jan.)Supplement 1 Page Start: S493 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. PTU-069 Effect of Adalimumab on Patients with Moderate to Severe Ulcerative Colitis in UK Clinical Practice Setting: Results from Inspirada. (17th August 2016) Authors: Irving, P; Cummings, F; Bloom, SL; Lazar, A; Robinson, AM; Pappalardo, BL; Bereswill, M; Skup, M; Chen, N; Finney-Hayward, T; Wang, S; Thakkar, RB; Travis, S Journal: Gut Issue: Volume 65(2016)Supplement 1 Page Start: A86 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. THU0525 Safety of adalimumab ± methotrexate for the treatment of polyarticular juvenile idiopathic arthritis (PJIA): strive registry. (15th June 2017) Authors: Ruperto, N; Brunner, H; Nanda, K; Toth, M; Foeldvari, I; Bohnsack, J; Milojevic, D; Rabinovich, C; Kingsbury, D; Marzan, K; Quartier, P; Minden, K; Chalom, E; Horneff, G; Kuester, R; Dare, J; Bereswill, M; Kalabic, J; Kupper, H; Martini, A Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 405 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗